Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Operating Expenses: 2010-2025

Historic Operating Expenses for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $15.5 million.

  • OptimizeRx's Operating Expenses fell 2972.87% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.8 million, marking a year-over-year decrease of 2238.85%. This contributed to the annual value of $73.1 million for FY2024, which is 545.73% up from last year.
  • OptimizeRx's Operating Expenses amounted to $15.5 million in Q3 2025, which was down 2972.87% from $15.4 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Operating Expenses registered a high of $28.7 million during Q4 2023, and its lowest value of $6.8 million during Q1 2021.
  • Moreover, its 5-year median value for Operating Expenses was $13.4 million (2023), whereas its average is $14.5 million.
  • Per our database at Business Quant, OptimizeRx's Operating Expenses skyrocketed by 11582.31% in 2023 and then crashed by 3602.71% in 2024.
  • Over the past 5 years, OptimizeRx's Operating Expenses (Quarter) stood at $11.8 million in 2021, then rose by 13.15% to $13.3 million in 2022, then skyrocketed by 115.82% to $28.7 million in 2023, then plummeted by 36.03% to $18.4 million in 2024, then fell by 15.9% to $15.5 million in 2025.
  • Its Operating Expenses was $15.5 million in Q3 2025, compared to $15.4 million in Q2 2025 and $15.5 million in Q1 2025.